Inactive Instrument

Biovica International AB Stock Nasdaq Stockholm

Equities

Biotechnology & Medical Research

End-of-day quote Nasdaq Stockholm
- SEK - Intraday chart for Biovica International AB
Sales 2024 * 10M 949K Sales 2025 * 116M 11.01M Capitalization 151M 14.36M
Net income 2024 * -115M -10.92M Net income 2025 * -60M -5.7M EV / Sales 2024 * 7.78 x
Net cash position 2024 * 73.52M 6.98M Net cash position 2025 * 45.95M 4.36M EV / Sales 2025 * 0.91 x
P/E ratio 2024 *
-0.24 x
P/E ratio 2025 *
-0.63 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 92.54%
More Fundamentals * Assessed data
Managers TitleAgeSince
Chief Executive Officer 54 09-12-31
Director of Finance/CFO 59 22-12-31
Chief Tech/Sci/R&D Officer 45 21-12-31
Members of the board TitleAgeSince
Chairman 64 19-03-19
Director/Board Member 61 19-12-31
Director/Board Member 68 15-12-31
More insiders
Biovica International AB is a Sweden-based biotechnology company. It develops and commercializes blood-based biomarker assays for the monitoring of cancer therapies and for prediction of patient outcome. The Company has focus on breast cancer and its main product DiviTum is a blood-based test, which measures the activity of the enzyme thymidine kinase-1 (TK) in blood serum or cell cultures. The Company collaborates with numerous institutions, such as Karolinska Institutet in Sweden and Dana Farber Cancer Institute, Washington University, Baylor College of Medicine, City of Hope Research & Treatment Center in the Unites States, as well as The International Breast Cancer Study Group (IBCSG) based in Switzerland and Breast International Group in Belgium.
Calendar
More about the company